CRL Stock Analysis: Charles River Laboratories | NYSE
Diagnostics & Research | NYSE, USA | Market Cap: 13.394m USD | 12M Return: 97% | US1598641074 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 258M
EPS Trend: -55.5%
Qual. Beats: 1
Rev. Trend: -89.0%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Charles River Laboratories International, Inc. (NYSE: CRL) is a global contract research organization (CRO) that supports the drug development lifecycle through three reporting segments: Research Models and Services (supplying purpose-bred rodents and related in vivo research support), Discovery and Safety Assessment (preclinical drug discovery, toxicology, pathology, and pharmacokinetics), and Manufacturing Solutions (biologics testing, quality control, and contract development and manufacturing).
The company operates across the United States, Europe, Canada, and the Asia Pacific, serving pharmaceutical and biotechnology clients with outsourced, non-clinical research and manufacturing services. Its business model is tied to early-stage biopharma R&D spending, as most services are performed prior to human clinical trials.
CRL maintains strategic collaborations with the Parker Institute for Cancer Immunotherapy, Childrens Hospital Los Angeles, and the Francis Crick Institute, including an alliance focused on antibody-drug conjugate (ADC) discovery and development. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts, and is classified within the Life Sciences Tools & Services sub-industry of the Health Care sector.
- Biotech R&D funding weakness pressures DSA bookings growth
- Research Models margins recover as NHP supply normalizes
- Manufacturing Solutions CDMO segment drives revenue mix shift toward higher margins
| Net Income: -238.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -2.73 > 1.0 |
| NWC/Revenue: 9.86% < 20% (prev 9.67%; Δ 0.20% < -1%) |
| CFO/TA 0.08 > 3% & CFO 582.1m > Net Income -238.5m |
| Net Debt (3.24b) to EBITDA (220.5m): 14.71 < 3 |
| Current Ratio: 1.35 > 1.5 & < 3 |
| Outstanding Shares: last quarter (48.5m) vs 12m ago -1.68% < -2% |
| Gross Margin: 32.24% > 18% (prev 32.47%; Δ -0.23% > 0.5%) |
| Asset Turnover: 52.99% > 50% (prev 53.28%; Δ -0.29% > 0%) |
| Interest Coverage Ratio: -0.73 > 6 (EBIT TTM -77.4m / Interest Expense TTM 106.3m) |
| A: 0.05 (Total Current Assets 1.53b - Total Current Liabilities 1.13b) / Total Assets 7.53b |
| B: 0.18 (Retained Earnings 1.37b / Total Assets 7.53b) |
| C: -0.01 (EBIT TTM -77.4m / Avg Total Assets 7.55b) |
| D: 0.61 (Book Value of Equity 2.84b / Total Liabilities 4.69b) |
| Altman-Z'' = 1.50 = BB |
| DSRI: 0.93 (Receivables 711.8m/767.6m, Revenue 4.00b/4.03b) |
| GMI: 1.01 (GM 32.47% / 32.24%) |
| AQI: 1.02 (AQ_t 0.55 / AQ_t-1 0.54) |
| SGI: 0.99 (Revenue 4.00b / 4.03b) |
| TATA: -0.11 (NI -238.5m - CFO 582.1m) / TA 7.53b) |
| Beneish M = -3.08 (Cap -4..+1) = AA |
As of September 25, 2026, the stock is trading at USD 294.44 with a total of 1,590,731 shares traded. Over the past week, the price has changed by +4.53%, over one month by -1.39%, over three months by +45.69% and over the past year by +97.02%.
Current recommended Stop Loss: 278.60 (which is 5.4% or 1.6 ATR below the current price).
Charles River Laboratories has received a consensus analysts rating of 3.32. Therefore, it is recommended to hold CRL.
- StrongBuy: 4
- Buy: 0
- Hold: 14
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 282.4 | -4.1% |
P/E Forward = 22.4719
P/S = 3.3492
P/B = 4.6746
P/EG = 0.1222
Revenue TTM = 4.00b USD
EBIT TTM = -77.4m USD
EBITDA TTM = 220.5m USD
Long Term Debt = 2.62b USD (from longTermDebt, last quarter)
Short Term Debt = 61.1m USD (from shortTermDebt, last fiscal year)
Debt = 3.44b USD (from shortLongTermDebtTotal, last quarter) + Leases 407.7m
Net Debt = 3.24b USD (calculated: Debt 3.44b - CCE 192.0m)
Enterprise Value = 16.6b USD (13.4b + Debt 3.44b - CCE 192.0m)
Interest Coverage Ratio = -0.73 (Ebit TTM -77.4m / Interest Expense TTM 106.3m)
EV/FCF = 44.89x (Enterprise Value 16.6b / FCF TTM 370.6m)
FCF Yield = 2.23% (FCF TTM 370.6m / Enterprise Value 16.6b)
FCF Margin = 9.27% (FCF TTM 370.6m / Revenue TTM 4.00b)
Net Margin = -5.96% (Net Income TTM -238.5m / Revenue TTM 4.00b)
Gross Margin = 32.24% ((Revenue TTM 4.00b - Cost of Revenue TTM 2.71b) / Revenue TTM)
Gross Margin QoQ = 36.19% (prev 28.05%)
Tobins Q-Ratio = 2.21 (Enterprise Value 16.6b / Total Assets 7.53b)
Interest Expense / Debt = 3.09% (Interest Expense 106.3m / Debt 3.44b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -61.2m (EBIT -77.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.35 (Total Current Assets 1.53b / Total Current Liabilities 1.13b)
Debt / Equity = 1.21 (Debt 3.44b / totalStockholderEquity, last quarter 2.84b)
Debt / EBITDA = 14.71 (Net Debt 3.24b / EBITDA 220.5m)
Debt / FCF = 8.75 (Net Debt 3.24b / FCF TTM 370.6m)
Total Stockholder Equity = 3.09b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.16% (Net Income -238.5m / Total Assets 7.53b)
RoE = -7.72% (Net Income TTM -238.5m / Total Stockholder Equity 3.09b)
RoCE = -1.36% (EBIT -77.4m / Capital Employed (Equity 3.09b + L.T.Debt 2.62b))
RoIC = -0.98% (negative operating profit) (NOPAT -61.2m / Invested Capital 6.27b)
WACC = 9.40% (E(13.4b)/V(16.8b) * Re(11.19%) + D(3.44b)/V(16.8b) * Rd(3.09%) * (1-Tc(0.21)))
Discount Rate = 11.19% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -96.67 | Cagr: -2.93%
[DCF] Terminal Value 69.25% ; FCFF base≈453.8m ; Y1≈397.9m ; Y5≈321.5m
[DCF] Fair Price = 23.95 (EV 4.40b - Net Debt 3.24b = Equity 1.15b / Shares 48.2m; r=9.40% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -55.53 | EPS CAGR: -2.05% | SUE: 1.69 | # QB: 1
Revenue Correlation: -88.98 | Revenue CAGR: -1.49% | SUE: 1.67 | # QB: 2
EPS current Quarter (2026-09-30): EPS=2.95 | Chg30d=+0.00% | Revisions=-62% | Analysts=11
EPS current Year (2026-12-31): EPS=11.33 | Chg30d=+0.12% | Revisions=+69% | GrowthEPS=+10.2% | GrowthRev=-2.6%
EPS next Year (2027-12-31): EPS=12.71 | Chg30d=+0.20% | Revisions=+71% | GrowthEPS=+12.2% | GrowthRev=+2.3%
[Analyst] Revisions Ratio: +38% (up=26, down=11)